Advanced search
Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Email Registration
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. United States
  4. Nyse
  5. Eli Lilly and Company
  6. News
  7. Summary
    LLY   US5324571083

ELI LILLY AND COMPANY

(LLY)
  Report
Delayed Nyse  -  04:03:05 2023-01-27 pm EST
342.10 USD   -1.70%
01/27Eli Lilly's Oncology Unit Gets US FDA's Approval for Mantle Cell Lymphoma Drug
MT
01/27FDA Approves Eli Lilly's Jaypirca to Treat Lymphoma Patients
DJ
01/27Eli Lilly Receives US FDA's Nod of Jaypirca to Treat Mantle Cell Lymphoma
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Eli Lilly's COVID drug bebtelovimab not currently authorized in U.S., says FDA

11/30/2022 | 02:59pm EST
share with twitter
share with LinkedIn
share with facebook
FILE PHOTO: An Eli Lilly and Co pharmaceutical manufacturing plant is pictured in Branchburg, New Jersey

(Reuters) - The U.S. Food and Drug Administration said on Wednesday Eli Lilly and Co's COVID-19 drug bebtelovimab is not currently authorized for emergency use in the country as it is not expected to neutralize the dominant BQ.1 and BQ.1.1 subvariants of Omicron.

(Reporting by Leroy Leo in Bengaluru; Editing by Sriraj Kalluvila)


© Reuters 2022
All news about ELI LILLY AND COMPANY
01/27Eli Lilly's Oncology Unit Gets US FDA's Approval for Mantle Cell Lymphoma Drug
MT
01/27FDA Approves Eli Lilly's Jaypirca to Treat Lymphoma Patients
DJ
01/27Eli Lilly Receives US FDA's Nod of Jaypirca to Treat Mantle Cell Lymphoma
MT
01/27FDA approves Eli Lilly's drug for rare blood cancer
RE
01/27FDA approves Eli Lilly's blood cancer drug
RE
01/27U.S. FDA Approves Jaypirca™ (pirtobrutinib), the First and Only Non-Covalent (Rev..
PR
01/27Eli Lilly and Company Announces That the U.S. Food and Drug Administration Approved Jay..
CI
01/27Eli Lilly's Diabetes Drug Recommended for Approval by European Medicines Agency Committ..
MT
01/26U.S. FDA pulls authorization for AstraZeneca's COVID-19 treatment Evusheld
RE
01/26Eli Lilly Earmarks $1 Million to Boost Cold Chain Capacity in 17 Countries
MT
More news
Analyst Recommendations on ELI LILLY AND COMPANY
More recommendations
Financials (USD)
Sales 2022 28 646 M - -
Net income 2022 6 111 M - -
Net Debt 2022 11 017 M - -
P/E ratio 2022 51,8x
Yield 2022 1,09%
Capitalization 325 B 325 B -
EV / Sales 2022 11,7x
EV / Sales 2023 10,9x
Nbr of Employees 35 000
Free-Float 99,8%
Chart ELI LILLY AND COMPANY
Duration : Period :
Eli Lilly and Company Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ELI LILLY AND COMPANY
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Last Close Price 342,10 $
Average target price 378,45 $
Spread / Average Target 10,6%
EPS Revisions
Managers and Directors
David A. Ricks Chairman, President & Chief Executive Officer
Anat Ashkenazi Chief Financial Officer & Senior Vice President
Daniel M. Skovronsky Chief Scientific Officer & Senior Vice President
Diogo Rau Senior VP, Chief Information & Digital Officer
Alonzo Weems Senior VP, Chief Ethics & Compliance Officer
Sector and Competitors
1st jan.Capi. (M$)
ELI LILLY AND COMPANY-4.87%325 056
JOHNSON & JOHNSON-4.77%439 835
NOVO NORDISK A/S1.06%312 363
ROCHE HOLDING AG-0.40%277 685
MERCK & CO., INC.-5.02%267 180
ABBVIE INC.-9.49%258 606